Oxidative DNA damage is important to the evolution of antibiotic resistance: evidence of mutation bias and its medicinal implications.
Several (1) studies have revealed that the reactive oxygen species (ROS) induced by antibacterial stimulation accelerates the evolution of antibiotic resistance, which uncovered new links between oxygen rise and evolution and inspired new strategies to prevent antibiotic resistance. Considering many other mechanisms cause DNA mutations aside from ROS damage, evaluating the significance of oxidative DNA damage in the development of antibiotic resistance is of great interest. In this study, we examined the ratio of G:C > T:A transversion to G:C > A:T transition in drug-resistant Escherichia coli and Mycobacterium tuberculosis and found that it is significantly higher than the background values. This finding strongly suggests that ROS damage plays a critical role in the development of antibacterial resistance. Considering the long-term co-evolution between host organisms and pathogenic bacteria, we speculate that the hosts may have evolved strategies for combating antibiotic resistance by controlling DNA damage in bacteria. Analysis of the global transcriptional profiles of Staphylococcus aureus treated with berberine (derived from Berberis, a traditional antibacterial medicine) revealed that the transcription of DNA repair enzymes was markedly upregulated, whereas the antioxidant enzymes were significantly downregulated. Thus, we propose that consolidating the DNA repair systems of bacteria may be a viable strategy for preventing antibiotic resistance. (1)These authors contributed equally to this work.
National Key Laboratory of Crop Genetic Improvement, Center for Bioinformatics, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, P.R. China.
Zhong-Yi
ZY
Wang
Min
M
Xiong
Liang-Yu
LY
Fu
Hong-Yu
HY
Zhang
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D005075:Biological Evolution; D004249:DNA Damage; D004260:DNA Repair; D004352:Drug Resistance, Microbial / Q000235:genetics*; D004926:Escherichia coli / Q000187:drug effects / Q000378:metabolism; D009154:Mutation; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000378:metabolism; D010084:Oxidation-Reduction; D017382:Reactive Oxygen Species; D013211:Staphylococcus aureus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D017382:Reactive Oxygen Species